Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/36224
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorPASQUALINI, Claudia
dc.contributor.authorFURTWAENGLER, Rhoikos
dc.contributor.authorTINTEREN, Harm van
dc.contributor.authorTEIXEIRA, Roberto A. P.
dc.contributor.authorACHA, Tomas
dc.contributor.authorHOWELL, Lisa
dc.contributor.authorVUJANIC, Gordan
dc.contributor.authorGODZINSKI, Jan
dc.contributor.authorMELCHIOR, Patrick
dc.contributor.authorSMETS, Anne M.
dc.contributor.authorCOULOMB-L'HERMINE, Aurore
dc.contributor.authorBRISSE, Herve
dc.contributor.authorPRITCHARD-JONES, Kathy
dc.contributor.authorBERGERON, Christophe
dc.contributor.authorCAMARGO, Beatriz de
dc.contributor.authorHEUVEL-EIBRINK, Marry M. Van den
dc.contributor.authorGRAF, Norbert
dc.contributor.authorVERSCHUUR, Arnauld C.
dc.date.accessioned2020-06-01T15:00:48Z-
dc.date.available2020-06-01T15:00:48Z-
dc.date.issued2020
dc.identifier.citationEUROPEAN JOURNAL OF CANCER, v.128, p.38-46, 2020
dc.identifier.issn0959-8049
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/36224-
dc.description.abstractIntroduction: High-risk (HR) metastatic (stage IV) Wilms tumours (WTs) have a particular poor outcome. Methods: Here, we report the results of HR (diffuse anaplastic [DA] or blastemal type [BT]) stage IV WT treated patients according to the HR arm in the SIOP2001 prospective study. Results: From January 2002 to August 2014, 3559 patients with WT were included in the SIOP2001 trial. Among the 525 patients (15%) with metastatic WT, 74 (14%) had stage IV HR-WT. The median age at diagnosis was 5.5 years (range: 1.4-18.3). Thirty-four patients (47%) had BT-WT and 40 (53%) had DA-WT. Five-year event-free survival rates were 44 +/- 17% and 28 +/- 15% for BT-WT and DA-WT, respectively (p = 0.09). Five-year overall survival rates were 53 +/- 17% and 29 +/- 16% for BT-WT and DA-WT, respectively (p = 0.03). Metastatic complete response after preoperative treatment was significantly associated with outcome in univariate and multivariate analyses (hazards ratio = 0.3; p = 0.01). Postoperative radiotherapy of metastatic sites might also be beneficial. Forty-three of 74 patients experienced a relapse or progression predominantly in the lungs (80%). The median time to relapse/ progression after diagnosis was 7.3 months (range: 1.6e33.3) and 4.9 months (range: 0.7 -28.4) for BT-WT and DA-WT, respectively (p Z 0.67). This is the first prospective evidence of inferior survival of stage IV BT-WT as compared with historical intermediate-risk WT. Survival of patients with stage IV DA-WT has not improved compared to the previous SIOP93-01 study. Conclusion: These results call for new treatment approaches for patients with HR stage IV WT.eng
dc.description.sponsorshipGerman CancerAid (Deutsche Krebshilfe)Deutsche Krebshilfe [50-2709-GR2]
dc.description.sponsorshipAssociation Leon Berard Enfant Cancereux
dc.description.sponsorshipEnfant et Sante(Albec)
dc.description.sponsorshipDaDa Society (Nieuwerkerk a/d Ijssel, The Netherlands)Netherlands Government
dc.description.sponsorshipPaediatric Oncology Centre Society for Research (KOCR, Rotterdam, the Netherlands)Netherlands Government
dc.description.sponsorshipGrupo Cooperativo Brasileiro para o Tratamento do tumour de Wilms (GCBTTW)
dc.description.sponsorshipSpanish Association Against Cancer (AECC)
dc.description.sponsorshipCancer Research UKCancer Research UK [C1010/A2889, C1188/A8687]
dc.description.sponsorshipNational Cancer Research Network
dc.description.sponsorshipSociete Francaise des Cancers de l'Enfant (SFCE)
dc.description.sponsorshipGesellschaft fur Paediatrische Onkologie und Haematologie (GPOH)
dc.description.sponsorshipChildren's Cancer and Leukemia Group (CCLG)
dc.description.sponsorshipSpanish Society of Paediatric Haematology and Oncology (SEHOP)
dc.description.sponsorshipSociedade Brasileira de Oncologia Pediatrica (SOBOPE)
dc.description.sponsorshipStichting Kinderoncologie Nederland (SKION)
dc.language.isoeng
dc.publisherELSEVIER SCI LTDeng
dc.relation.ispartofEuropean Journal of Cancer
dc.rightsrestrictedAccesseng
dc.subjectWilmseng
dc.subjectAnaplasiaeng
dc.subjectBlastemaeng
dc.subjectCancereng
dc.subjectChildeng
dc.subjectTP53eng
dc.subject.otherinternational-societyeng
dc.subject.otherdiffuse anaplasiaeng
dc.subject.otherchildreneng
dc.subject.othernephroblastomaeng
dc.subject.othertrialeng
dc.subject.othersurvivaleng
dc.titleOutcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Groupeng
dc.typearticleeng
dc.rights.holderCopyright ELSEVIER SCI LTDeng
dc.identifier.doi10.1016/j.ejca.2020.01.001
dc.identifier.pmid32109849
dc.subject.wosOncologyeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalPASQUALINI, Claudia:Gustave Roussy, Children & Adolescents Oncol Dept, Villejuif, France
hcfmusp.author.externalFURTWAENGLER, Rhoikos:Saarland Univ Hosp, Dept Pediat Haematol Oncol, Homburg, Germany
hcfmusp.author.externalTINTEREN, Harm van:Netherlands Canc Inst, Biometr Dept, Amsterdam, Netherlands
hcfmusp.author.externalACHA, Tomas:Hosp Maternoinfantil Carlos Haya, Dept Pediat, Malaga, Spain
hcfmusp.author.externalHOWELL, Lisa:Alder Hey Childrens NHS Fdn Trust, Dept Oncol, Liverpool, Merseyside, England
hcfmusp.author.externalVUJANIC, Gordan:Sidra Med, Dept Pathol, Doha, Qatar
hcfmusp.author.externalGODZINSKI, Jan:Marciniak Hosp Wroclaw, Dept Pediat Surg, Wroclaw, Poland; Med Univ, Dept Pediat Traumatol & Emergency Med, Wroclaw, Poland
hcfmusp.author.externalMELCHIOR, Patrick:Saarland Univ Hosp, Dept Radiat Oncol, Homburg, Germany
hcfmusp.author.externalSMETS, Anne M.:Acad Med Ctr, Dept Radiol & Nucl Med, Amsterdam, Netherlands
hcfmusp.author.externalCOULOMB-L'HERMINE, Aurore:Hosp Enfants Armand Trousseau, Dept Pathol, Paris, France
hcfmusp.author.externalBRISSE, Herve:Curie Inst, Dept Radiol, Paris, France
hcfmusp.author.externalPRITCHARD-JONES, Kathy:UCL, Great Ormond St Inst Child Hlth, London, England
hcfmusp.author.externalBERGERON, Christophe:Ctr Leon Berard, Pediat Oncohaematol Dept, Lyon, France
hcfmusp.author.externalCAMARGO, Beatriz de:Inst Nacl Canc, Pediat Oncohaematol, Rio De Janeiro, Brazil
hcfmusp.author.externalHEUVEL-EIBRINK, Marry M. Van den:Princess Maxima Ctr Pediat Oncol, Oncol, Utrecht, Netherlands; Dutch Childhood Oncol Grp, The Hague, Netherlands
hcfmusp.author.externalGRAF, Norbert:Saarland Univ Hosp, Dept Pediat Haematol Oncol, Homburg, Germany
hcfmusp.author.externalVERSCHUUR, Arnauld C.:Hop La Timone, AP HM, Pediat Oncohaematol Dept, Marseille, France
hcfmusp.description.beginpage38
hcfmusp.description.endpage46
hcfmusp.description.volume128
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000520115100005
hcfmusp.origem.id2-s2.0-85079007109
hcfmusp.publisher.cityOXFORDeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceAbu-Ghosh AM, 2002, ANN ONCOL, V13, P460, DOI 10.1093/annonc/mdf028eng
hcfmusp.relation.referenceChagtai T, 2016, J CLIN ONCOL, V34, P3195, DOI 10.1200/JCO.2015.66.0001eng
hcfmusp.relation.referenceDaw NC, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.10032eng
hcfmusp.relation.referenceDome JS, 2006, J CLIN ONCOL, V24, P2352, DOI 10.1200/JCO.2005.04.7852eng
hcfmusp.relation.referenceFurtwangler R, 2011, KLIN PADIATR, V223, P113, DOI 10.1055/s-0031-1275293eng
hcfmusp.relation.referenceGraf N, 2012, EUR J CANCER, V48, P3240, DOI 10.1016/j.ejca.2012.06.007eng
hcfmusp.relation.referenceGREEN DM, 1994, J CLIN ONCOL, V12, P2126, DOI 10.1200/JCO.1994.12.10.2126eng
hcfmusp.relation.referenceHa TC, 2013, EUR J CANCER, V49, P194, DOI 10.1016/j.ejca.2012.07.010eng
hcfmusp.relation.referenceHol JA, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26849eng
hcfmusp.relation.referenceJimenez I, 2019, INT J CANCER, V144, P68, DOI 10.1002/ijc.31620eng
hcfmusp.relation.referenceKremens B, 2002, BONE MARROW TRANSPL, V30, P893, DOI 10.1038/sj.bmt.1703771eng
hcfmusp.relation.referenceLudwig N, 2015, PEDIATR BLOOD CANCER, V62, P1360, DOI 10.1002/pbc.25481eng
hcfmusp.relation.referenceOoms AHAG, 2016, CLIN CANCER RES, V22, P5582, DOI 10.1158/1078-0432.CCR-16-0985eng
hcfmusp.relation.referencePastore G, 2006, EUR J CANCER, V42, P2103, DOI 10.1016/j.ejca.2006.05.010eng
hcfmusp.relation.referenceReinhard H, 2004, KLIN PADIATR, V216, P132, DOI 10.1055/s-2004-822625eng
hcfmusp.relation.referenceSpreafico F, 2017, NAT REV UROL, V14, P3, DOI 10.1038/nrurol.2016.247eng
hcfmusp.relation.referenceTreger TD, 2018, TRANSL ONCOL, V11, P1301, DOI 10.1016/j.tranon.2018.08.006eng
hcfmusp.relation.referencevan den Heuvel-Eibrink MM, 2015, EUR J CANCER, V51, P498, DOI 10.1016/j.ejca.2014.12.011eng
hcfmusp.relation.referencevan den Heuvel-Eibrink MM, 2017, NAT REV UROL, V14, P743, DOI 10.1038/nrurol.2017.163eng
hcfmusp.relation.referenceVerschuur A, 2012, J CLIN ONCOL, V30, P3533, DOI 10.1200/JCO.2011.35.8747eng
hcfmusp.relation.referenceVujanic GM, 1999, MED PEDIATR ONCOL, V32, P317, DOI 10.1002/(SICI)1096-911X(199905)32:5<317::AID-MPO1>3.0.CO;2-Feng
hcfmusp.relation.referenceVujanic GM, 2002, MED PEDIATR ONCOL, V38, P79, DOI 10.1002/mpo.1276eng
hcfmusp.relation.referenceWegert J, 2017, J PATHOL CLIN RES, V3, P234, DOI 10.1002/cjp2.77eng
hcfmusp.relation.referenceWeirich A, 2004, ANN ONCOL, V15, P808, DOI 10.1093/annonc/mdh171eng
hcfmusp.relation.referenceZUPPAN CW, 1988, HUM PATHOL, V19, P1199, DOI 10.1016/S0046-8177(88)80152-7eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1879-0852
hcfmusp.citation.scopus13-
hcfmusp.scopus.lastupdate2022-04-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICr
Instituto da Criança - HC/ICr

Artigos e Materiais de Revistas Científicas - LIM/36
LIM/36 - Laboratório de Pediatria Clínica

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_PASQUALINI_Outcome_of_patients_with_stage_IV_highrisk_Wilms_2020.PDF
  Restricted Access
publishedVersion (English)1.45 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.